PDS Biotechnology gets FDA fast track status for PDS0101
PDS Biotechnology has secured fast track designation to its PDS0101 in combination with Merck’s KEYTRUDA (pembrolizumab) from the US Food and Drug Administration (FDA) for the treatment of HPV16-positive head and neck cancer that is recurrent or metastatic. The US-based clinical-stage immunotherapy company is currently evaluating the combination of PDS0101 and KEYTRUDA in the VERSATILE-002 […]